United States v. Fresenius Medical Care AG & Co. KGAA

District Court, E.D. New York·Decided July 30, 2021·No. 1:14-cv-06646·Unknown

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK ---------------------------------------------------------- X : UNITED STATES OF AMERICA ex rel. : CKD PROJECT, LLC, : ORDER ADOPTING REPORT AND : RECOMMENDATION Plaintiff, : : 14-cv-6646 (BMC) (SJB) - against - : : FRESENIUS MEDICAL CARE : HOLDINGS, INC.; NEW YORK DIALYSIS : SERVICES, INC.; FMS NEW YORK : SERVICES LLC; and BIO-MEDICAL : APPLICATIONS MANAGEMENT : COMPANY, INC.; : : Defendants. : : ---------------------------------------------------------- X

COGAN, District Judge.

In this case under the False Claims Act (“FCA”), relator CKD Project, LLC, sued various entities connected to Fresenius Medical Care Holdings, Inc. (collectively, “defendants”), alleging that they maintained a “systematic and nationwide kickback scheme” in violation of the Anti- Kickback Statute (“AKS”), 42 U.S.C. § 1320a-7b(b). In a Report and Recommendation (“R&R”), Magistrate Judge Bulsara recommended dismissing the suit based on the “public disclosure bar.” Now before me are relator’s objections. “A judge of the [district] court may accept, reject, or modify, in whole or in part, the findings or recommendations made by the magistrate judge.” 28 U.S.C. § 636(b)(1). Although review is de novo for “those portions of the report . . . to which objection is made,” id., a report “should be reviewed only for clear error” when a party “simply reiterates his original arguments,” Bridges v. Lee, No. 15-cv-4669, 2021 WL 688292, at *2 (E.D.N.Y. Feb. 23, 2021). Relator’s objections fall mostly in the latter category. In any event, I see no error, much less clear error, in the R&R.1 1. Relator first argues that the public disclosure bar does not apply to this case. The public disclosure bar provides that courts ‘shall dismiss an action or claim . . . if substantially the same allegations or transactions as alleged in the action or claim were publicly disclosed . . .

unless . . . the person bringing the action is an original source of the information.” United States ex rel. Chorches for Bankr. Est. of Fabula v. Am. Med. Response, Inc., 865 F.3d 71, 79 (2d Cir. 2017) (quoting 31 U.S.C. § 3730(e)(4)(A)). The public disclosure bar thus requires a two-step inquiry. First, “courts look to whether the substance of a relator’s claim had been disclosed prior to the filing of his suit,” and second, “courts look to whether, if such disclosures had been made, the relator can be considered an ‘original source.’” United States ex rel. Patriarca v. Siemens Healthcare Diagnostics, Inc., 295 F. Supp. 3d 186, 196 (E.D.N.Y. 2018). At the first step, the R&R concluded that the substance of relator’s claim had been disclosed in the 2013 Form 20-F that Fresenius Medical Care AG & Co. KGaA filed with the

Securities and Exchange Commission. It provided: If our joint ventures violate the law, our business could be adversely affected. A number of the dialysis centers and vascular access centers we operate are owned, or managed, by joint ventures in which we hold a controlling interest and one or more hospitals, physicians or physician practice groups hold a minority interest. Physician owners, who are usually nephrologists, may also provide medical director services and physician owners may refer patients to those centers or other centers we own or operate or to other physicians who refer patients to those centers or other centers we own and operate. While we have structured our

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Fresenius Medical Care AG & Co. KGAA, (E.D.N.Y. 2021).

United States v. Fresenius Medical Care AG & Co. KGAA (United States v. Fresenius Medical Care AG & Co. KGAA) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Holmes v. Grubman
568 F.3d 329 (Second Circuit, 2009)
United States ex rel. Vierczhalek v. Medimmune, Inc.
345 F. Supp. 3d 456 (S.D. Illinois, 2018)